drugs behave in children, but they come with heightened ethical scrutiny and regulatory complexity. Children are a vulnerable population, and involving them in early-phase trials—especially when risks are unknown—requires a rigorous justification and protective framework. This article outlines the ethical, operational, and regulatory challenges of pediatric Phase 1 trials and offers practical strategies to design and conduct them responsibly.

Why Pediatric Phase 1 Trials Are Challenging

• Ethical complexity: Involves balancing risk, benefit, and parental decision-making
• Limited preclinical and adult data: May not fully extrapolate to pediatric populations
• Variable developmental stages: Pharmacokinetics and pharmacodynamics differ by age
• Recruitment challenges: Smaller pools, increased anxiety, and burden on families

Ethical Considerations

1. Minimal Risk Principle

• Trials must demonstrate minimal risk unless direct benefit to the child is possible
• Risk-benefit must be justified by prior data or strong biological rationale

2. Informed Consent and Assent

• Parental consent required in all cases
• Child assent needed typically starting at age 7 or as per local guidelines
• Use child-friendly explanations and media

3. Ethical Review

• Must be reviewed by an IRB/IEC with pediatric experience
• Independent ethics consultants often required for FIH trials in children

Design Constraints in Pediatric Phase 1 Studies

1. Dose Selection

• Usually starts below adult minimum effective dose (MABEL preferred)
• Adjusted for weight, age, and organ function

2. Sample Collection Minimization

• Cap blood volume based on body weight (e.g., 3–5% of total volume)
• Use sparse sampling or population PK approaches

3. Age Stratification

• Infants, toddlers, school-age, and adolescents may be separated for PK assessment

Regulatory Frameworks

FDA (Pediatric Research Equity Act – PREA, BPCA)

• Allows pediatric studies only if adult safety data available or justified by disease severity
• Pediatric Study Plans (PSPs) required

EMA (Pediatric Investigation Plans – PIPs)

• Mandates PIPs for all new drug applications unless a waiver is granted
• Requires age-appropriate formulations and safety justification

CDSCO

• Requires separate ethics and CDSCO approval for pediatric studies
• Audio-visual consent mandatory with parental involvement

Best Practices

• Include pediatricians, ethicists, and patient advocates in protocol development
• Design flexible schedules to reduce burden on school and family life
• Utilize micro-sampling and non-invasive techniques (e.g., saliva PK, wearable devices)
• Offer psychological support and education for both children and caregivers
• Report safety events in real time with pediatric-specific oversight committees